Clinical Trial: Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: Study of Administration of Intravenous Naglazyme® Following Allogeneic Transplantation for Maroteaux-Lamy Syndrome

Brief Summary: This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant.